Zosano Pharma Corp. (ZSAN) has enrolled the first subject in a pivotal efficacy trial of its ZP-Triptan patch treatment for acute migraine. The company expects to report pivotal efficacy data from the trial in the first quarter of 2017.
Forex – financial instrument.Forex news
Zosano Pharma Corp. (ZSAN) has enrolled the first subject in a pivotal efficacy trial of its ZP-Triptan patch treatment for acute migraine. The company expects to report pivotal efficacy data from the trial in the first quarter of 2017.